TLR4 agonists as immunomodulatory agents

Area of Science:

• Immunology
• Vaccinology
• Synthetic Chemistry

Background:

• Monophosphoryl lipid A (MPL) is a licensed vaccine adjuvant derived from Salmonella minnesota.
• MPL signals through the Toll-like receptor 4 (TLR4)/MD-2 complex.
• There is a need for novel vaccine adjuvants, particularly for mucosal administration.

Purpose of the Study:

• To synthesize and characterize novel TLR4 agonists based on MPL structure.
• To evaluate the immunomodulatory and adjuvant properties of these synthetic agonists, termed aminoalkyl glucosaminide phosphates (AGPs).
• To explore the potential of AGPs in developing advanced mucosal vaccines.

Main Methods:

• Synthesis of a series of aminoalkyl glucosaminide phosphates (AGPs).
• In vitro studies using human peripheral blood mononuclear cells (PBMCs) to assess cytokine production and cell surface marker expression.
• In vivo studies in mice to evaluate non-specific resistance to viral and bacterial challenge after airway administration.
• Structure-activity relationship (SAR) studies to identify key molecular determinants for immune activation.

Main Results:

• AGPs effectively stimulate cytokine production and up-regulate cell surface markers on immune cells (monocytes, NK cells, B cells).
• Airway administration of AGPs confers non-specific resistance against viral and bacterial pathogens in mice.
• SAR studies indicate that acyl chain length and aglycon functional groups are critical for AGP activity.
• AGPs act as potent adjuvants for mucosal vaccine antigens, enhancing both antibody and cell-mediated immune responses.

Conclusions:

• AGPs are potent synthetic TLR4 agonists with significant immunomodulatory and adjuvant properties.
• AGPs can induce innate resistance and enhance adaptive immunity when administered mucosally.
• The findings suggest that AGPs hold promise for the development of next-generation mucosal vaccines offering immediate innate protection and durable acquired immunity.